CD19 and congenital rubella syndrome: Comparative effectiveness analyses revealed comparable incidence rates of grade ≥ 3 CRS (5%–15%) across CD19-targeted constructs, including axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tisa-cel) [7, 8].